POM-V Prescription Required

HorStem Suspension for Injection for Horses

Active ingredient: Equine umbilical cord mesenchymal stem cells

Form

Injection

Species

Horses

Manufacturer

EquiCord-YMAS S.L.

VMD MA No.

46422/5000

What it's used for

Reduction of lameness associated with mild to moderate degenerative joint disease (osteoarthritis) in horses.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Equine umbilical cord mesenc...

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

HorStem Suspension for Injection for Horses — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Reduction of lameness associated with mild to moderate degenerative joint disease
(osteoarthritis) in horses.

Route of administration:
Intraarticular use.
Dosage:
A single intraarticular injection of 1 ml (15x106 equine umbilical cord mesenchymal stem
cells) into the affected joint.
Method of administration:

The veterinary product must be administered intraarticularly, only by a veterinary surgeon,
taking special precautions to ensure the sterility of the injection process. The product must
be handled and injected following sterile techniques and in a clean environment.
Swirl gently before use in order to ensure the contents are well mixed.
Use a 20G needle.
Intraarticular placement should be confirmed by the appearance of synovial fluid in the hub
of the needle.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Very common:
Acute synovitis with an acute onset of severe lameness, joint effusion and pain on
palpation was reported 24 hours after administration of the veterinary medicinal product.
Substantial improvement was shown in the next 48 hours and complete remission in the
following two weeks. In case of severe inflammation, administration of symptomatic
treatment with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) could be necessary.
Common:
Moderate joint effusion with no associated lameness has been observed 24 hours after
HorStem administration. Complete remission was observed over the following two weeks
without any symptomatic treatment.
An increase in mild lameness was observed 24 hours after HorStem administration.
Complete remission was observed within 3 days, without any symptomatic treatment.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

The veterinary medicinal product was demonstrated to be efficacious in horses affected by
osteoarthritis in the metacarpo-phalangeal joint, distal interphalangeal joint, and
tarsometatarsal/ distal intertarsal joint. No efficacy data are available regarding the
treatment of other joints.
No efficacy data are available regarding the treatment in more than one arthritic joint at the
same time.
The onset of efficacy may be gradual. Efficacy data demonstrated an effect from 35 days
after treatment.

Revised: December 2021
AN: 01109/2021

Special precautions for use in animals
Correct placement of the needle is crucial to avoid accidental injection into blood vessels
and an associated risk of thrombosis.

The safety of the veterinary medicinal product has only been investigated in horses at
least two years old.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Care should be taken to avoid accidental self-injection.
Wash hands after use.
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.

Do not administer simultaneously with any other intraarticular veterinary medicinal product.

Store and transport refrigerated (2 C – 8 C).
Do not freeze.

Zero days.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.